624 related articles for article (PubMed ID: 34906598)
1. Targeting the NLRP3 inflammasome in cardiovascular diseases.
Toldo S; Mezzaroma E; Buckley LF; Potere N; Di Nisio M; Biondi-Zoccai G; Van Tassell BW; Abbate A
Pharmacol Ther; 2022 Aug; 236():108053. PubMed ID: 34906598
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases.
Mezzaroma E; Abbate A; Toldo S
Molecules; 2021 Feb; 26(4):. PubMed ID: 33673188
[TBL] [Abstract][Full Text] [Related]
4. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.
Toldo S; Abbate A
Nat Rev Cardiol; 2024 Apr; 21(4):219-237. PubMed ID: 37923829
[TBL] [Abstract][Full Text] [Related]
5. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
[TBL] [Abstract][Full Text] [Related]
6. The zebrafish NLRP3 inflammasome has functional roles in ASC-dependent interleukin-1β maturation and gasdermin E-mediated pyroptosis.
Li JY; Wang YY; Shao T; Fan DD; Lin AF; Xiang LX; Shao JZ
J Biol Chem; 2020 Jan; 295(4):1120-1141. PubMed ID: 31852739
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis.
Potere N; Garrad E; Kanthi Y; Di Nisio M; Kaplanski G; Bonaventura A; Connors JM; De Caterina R; Abbate A
Cardiovasc Res; 2023 Sep; 119(11):2046-2060. PubMed ID: 37253117
[TBL] [Abstract][Full Text] [Related]
8. The leucine-rich repeat (LRR) domain of NLRP3 is required for NLRP3 inflammasome activation in macrophages.
Duan Y; Wang J; Cai J; Kelley N; He Y
J Biol Chem; 2022 Dec; 298(12):102717. PubMed ID: 36403854
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease.
Vecchié A; Del Buono MG; Chiabrando GJ; Dentali F; Abbate A; Bonaventura A
Curr Cardiol Rep; 2021 Oct; 23(11):157. PubMed ID: 34599390
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
[TBL] [Abstract][Full Text] [Related]
11. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Grebe A; Hoss F; Latz E
Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
[TBL] [Abstract][Full Text] [Related]
12. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.
Liu X; Pichulik T; Wolz OO; Dang TM; Stutz A; Dillen C; Delmiro Garcia M; Kraus H; Dickhöfer S; Daiber E; Münzenmayer L; Wahl S; Rieber N; Kümmerle-Deschner J; Yazdi A; Franz-Wachtel M; Macek B; Radsak M; Vogel S; Schulte B; Walz JS; Hartl D; Latz E; Stilgenbauer S; Grimbacher B; Miller L; Brunner C; Wolz C; Weber ANR
J Allergy Clin Immunol; 2017 Oct; 140(4):1054-1067.e10. PubMed ID: 28216434
[TBL] [Abstract][Full Text] [Related]
13. Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.
An N; Gao Y; Si Z; Zhang H; Wang L; Tian C; Yuan M; Yang X; Li X; Shang H; Xiong X; Xing Y
Front Immunol; 2019; 10():1592. PubMed ID: 31354731
[TBL] [Abstract][Full Text] [Related]
14. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.
Potere N; Del Buono MG; Caricchio R; Cremer PC; Vecchié A; Porreca E; Dalla Gasperina D; Dentali F; Abbate A; Bonaventura A
EBioMedicine; 2022 Nov; 85():104299. PubMed ID: 36209522
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1.
Del Buono MG; Bonaventura A; Vecchié A; Moroni F; Golino M; Bressi E; De Ponti R; Dentali F; Montone RA; Kron J; Lazzerini PE; Crea F; Abbate A
Eur J Clin Invest; 2024 Feb; 54(2):e14110. PubMed ID: 37837616
[TBL] [Abstract][Full Text] [Related]
18. NLRP3, the inflammasome and COVID-19 infection.
Yin M; Marrone L; Peace CG; O'Neill LAJ
QJM; 2023 Jul; 116(7):502-507. PubMed ID: 36661317
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 inflammasome as a key driver of vascular disease.
Takahashi M
Cardiovasc Res; 2022 Jan; 118(2):372-385. PubMed ID: 33483732
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 inflammasome in endothelial dysfunction.
Bai B; Yang Y; Wang Q; Li M; Tian C; Liu Y; Aung LHH; Li PF; Yu T; Chu XM
Cell Death Dis; 2020 Sep; 11(9):776. PubMed ID: 32948742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
